Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy

Current Medical Research and Opinion

Volumn 22, Issue 7, 2006, Pages 1369-1373

  Mazokopakis, Elias E ^a,b,e   Starakis, Ioannis K ^c   Papadomanolaki, Maria G ^d   Batistakis, Antony G ^b   Papadakis, John A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Naval Hospital of Crete   (Greece)

^c UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^d TECHNICAL UNIVERSITY OF CRETE   (Greece)

^e Iroon Polytechniu 38A   (Greece)

Author keywords

Bone mineral density; Levothyroxine; Pre menopausal women; Suppressive therapy

Indexed keywords

IODINE 131; LEVOTHYROXINE;

ADULT; ANAMNESIS; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; LABORATORY TEST; PAPILLARY CARCINOMA; PREMENOPAUSE; SIDE EFFECT; STUDENT T TEST; THYROID CANCER; THYROIDECTOMY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 33746112341     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X115612     Document Type: Article

References (21)

1. Pagano L, Klain M, Pulcrano M, et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004;29:161-74
2. Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:62-9
3. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119: 492-502
4. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Eur J Endocrinol 1994;130:350-6
5. Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes 2003;111:455-70
6. Biondi B, Palmieri EA, Klain M, et al. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152:1-9
7. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:1-33
8. Chen CH, Chen JF, Yang BY, et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 2004;103:442-7
9. Heijckmann AC, Huijberts MS, Geusens P, et al. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005;153:23-9
10. Mikosch P, Jauk B, Gallowitsch HJ, et al. Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 2001;11:257-63
11. Franklyn JA, Betteridge J, Daykin J, et al. Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9-13
12. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991;72:1184-8
13. Pioli G, Pedrazzoni M, Palummeri E, et al. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta Endocrinol (Copenh) 1992;126:238-42
14. McDermott MT, Perloff JJ, Kidd GS. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif Tissue Int 1995;56:521-5
15. Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83:2324-30
16. Salamone LM, Cauley JA, Black DM, et al. Effect of a lifestyle intervention on bone mineral density in premenopausal women: a randomized trial. Am J Clin Nutr 1999;70:97-103
17. Orozco P, Nolla JM. Associations between body morphology and bone mineral density in premenopausal women. Eur J Epidemiol 1997;13:919-24
18. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998;128:386-94
19. Sert M, Tetiker T. Effects of L-thyroxine suppressive therapy on bone mineral density. Ann Med Sci 2002;11:21-4
20. Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259:3137-41
21. Ross DS, Neer RM, Ridgway EC, et al. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987;82:1167-70